GSK (GSK) plc announced the authorization of Blenrep by the Medicines and Healthcare products Regulatory Agency. “In the UK, Blenrep is approved for the treatment of adults with multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone (BPd) in patients who have received at least one prior therapy including lenalidomide. This UK regulatory authorisation marks the first in the world for Blenrep in this treatment setting,” the company reported.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK ‘pleased’ ACIP voted in favor of using RSV vaccines
- GSK ‘s meningococcal vaccine receives positive recommendation in the U.S.
- GSK initiated with a Neutral at BNP Paribas Exane
- CDC slides suggest ‘positive surprise’ for GSK, says Goldman Sachs
- GSK CEO says the company can navigate through the tariffs, Bloomberg says